| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Wendy S Garrett | Q91152376 |
| P2860 | cites work | Fusobacterium nucleatum: an emerging gut pathogen? | Q37954058 |
| NF-κB and the link between inflammation and cancer | Q37995696 | ||
| From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa | Q38142595 | ||
| A view to a kill: the bacterial type VI secretion system | Q38170842 | ||
| The mechanism of action of BCG therapy for bladder cancer--a current perspective | Q38184849 | ||
| Dysbiosis in the inflamed intestine: chance favors the prepared microbe. | Q38196672 | ||
| Linking microbial community structure, interactions and function in anaerobic digesters using new molecular techniques | Q38215152 | ||
| Bacteria: prospective savior in battle against cancer. | Q38264881 | ||
| Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. | Q38274609 | ||
| Co-occurrence of anaerobic bacteria in colorectal carcinomas. | Q38578821 | ||
| Streptococcus cristatus modulates the Fusobacterium nucleatum-induced epithelial interleukin-8 response through the nuclear factor-kappa B pathway | Q39552605 | ||
| Differential activation of NF-kappaB and gene expression in oral epithelial cells by periodontal pathogens. | Q40159973 | ||
| Escherichia coli induces DNA double-strand breaks in eukaryotic cells. | Q40244785 | ||
| New approaches for isolation of previously uncultivated oral bacteria | Q40311047 | ||
| Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder | Q40625152 | ||
| Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite? | Q42003419 | ||
| Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome | Q42257409 | ||
| IL-11: a prominent pro-tumorigenic member of the IL-6 family | Q42837727 | ||
| Breakthrough of the year 2013. Cancer immunotherapy | Q43822796 | ||
| G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. | Q54404790 | ||
| A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours | Q71803282 | ||
| Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples | Q21090158 | ||
| Combination bacteriolytic therapy for the treatment of experimental tumors | Q24555050 | ||
| Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma | Q24603069 | ||
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma | Q24603176 | ||
| Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation | Q24626051 | ||
| A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses | Q24630221 | ||
| A core gut microbiome in obese and lean twins | Q24649648 | ||
| Wnt/β-catenin signaling and disease | Q26823272 | ||
| Disease tolerance as a defense strategy | Q26828371 | ||
| Obesity and cancer: at the crossroads of cellular metabolism and proliferation | Q27003989 | ||
| The multifaceted role of the intestinal microbiota in colon cancer | Q27015657 | ||
| Interactions between the microbiota and the immune system | Q27028155 | ||
| Salmonella uses energy taxis to benefit from intestinal inflammation | Q27335357 | ||
| Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme | Q27665609 | ||
| Molecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity | Q27678202 | ||
| On the Origin of Cancer Cells | Q27861025 | ||
| Protein delivery into eukaryotic cells by type III secretion machines | Q28276443 | ||
| Environmentally controlled invasion of cancer cells by engineered bacteria | Q28285227 | ||
| Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment | Q28296759 | ||
| A functional role for Nlrp6 in intestinal inflammation and tumorigenesis | Q28508154 | ||
| Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 | Q28509150 | ||
| Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer | Q28592907 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| Gut inflammation provides a respiratory electron acceptor for Salmonella | Q29615318 | ||
| The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis | Q29616351 | ||
| Inflammatory mechanisms in obesity | Q29617932 | ||
| Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells | Q29618126 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation | Q29620116 | ||
| Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Q29620303 | ||
| Obesity and the human microbiome | Q30052740 | ||
| Obesity and cancer pathogenesis. | Q30361298 | ||
| Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes | Q30436566 | ||
| The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide | Q31144277 | ||
| Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. | Q33804327 | ||
| The gut microbiome modulates colon tumorigenesis | Q35032207 | ||
| The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment | Q35034370 | ||
| Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. | Q35050169 | ||
| Microbes, microbiota, and colon cancer | Q35120938 | ||
| The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients | Q35152783 | ||
| Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. | Q35163017 | ||
| Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis | Q35217096 | ||
| Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota | Q35409022 | ||
| Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses | Q35446009 | ||
| Gallbladder cancer: lessons from a rare tumour | Q35877178 | ||
| Gut microbiota-derived propionate reduces cancer cell proliferation in the liver | Q36387826 | ||
| Consistent activation of the β-catenin pathway by Salmonella type-three secretion effector protein AvrA in chronically infected intestine | Q36454282 | ||
| NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. | Q36580437 | ||
| Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. | Q36646662 | ||
| Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth | Q36696555 | ||
| Intestinal inflammation targets cancer-inducing activity of the microbiota. | Q36819342 | ||
| Exploiting social evolution in biofilms. | Q36823972 | ||
| The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. | Q37144338 | ||
| Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin | Q37164254 | ||
| Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. | Q37410263 | ||
| Comparative analysis of Salmonella genomes identifies a metabolic network for escalating growth in the inflamed gut. | Q37667983 | ||
| Diverse Toll-like receptors mediate cytokine production by Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans in macrophages | Q37713357 | ||
| Gastrointestinal malignancy and the microbiome. | Q37716976 | ||
| Host-derived nitrate boosts growth of E. coli in the inflamed gut | Q37731297 | ||
| Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage | Q37845554 | ||
| Do bacterial genotoxins contribute to chronic inflammation, genomic instability and tumor progression? | Q37876491 | ||
| Targeting cancer metabolism: a therapeutic window opens | Q37924094 | ||
| Synthetic biology moving into the clinic | Q37925394 | ||
| The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer | Q33839949 | ||
| PathSeq: software to identify or discover microbes by deep sequencing of human tissue | Q33892322 | ||
| Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack | Q34043164 | ||
| The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. | Q34047880 | ||
| The relationship of the oral microbiotia to periodontal health and disease | Q34054058 | ||
| Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway | Q34113327 | ||
| Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer | Q34137586 | ||
| Landscape of genomic alterations in cervical carcinomas | Q34169464 | ||
| Global distribution of microbial abundance and biomass in subseafloor sediment | Q34296356 | ||
| Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation | Q34311369 | ||
| Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics | Q34311685 | ||
| Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. | Q34360221 | ||
| Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome | Q34362427 | ||
| Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. | Q34411406 | ||
| Obesity and cancer--mechanisms underlying tumour progression and recurrence | Q34425077 | ||
| Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. | Q34429647 | ||
| The gut microbiota, bacterial metabolites and colorectal cancer | Q34437334 | ||
| The impact of intestinal inflammation on the nutritional environment of the gut microbiota | Q34451272 | ||
| Nutrients, foods, and colorectal cancer prevention | Q34457478 | ||
| The human gut microbiome as a screening tool for colorectal cancer. | Q34457985 | ||
| Epidemiology and molecular pathology of gallbladder cancer | Q34473041 | ||
| Microbial interactions in building of communities | Q34518087 | ||
| High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity | Q34518703 | ||
| Short hairpin RNA-expressing bacteria elicit RNA interference in mammals | Q34525784 | ||
| Fusobacterium is associated with colorectal adenomas | Q34555713 | ||
| Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea | Q34610452 | ||
| Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology | Q34615534 | ||
| A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner | Q34644406 | ||
| Microbiota organization is a distinct feature of proximal colorectal cancers | Q34793322 | ||
| Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice | Q34794391 | ||
| Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis | Q35008903 | ||
| IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation | Q35013368 | ||
| The microbiome and cancer | Q35019302 | ||
| Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms | Q35024882 | ||
| P433 | issue | 6230 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 80-86 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Cancer and the microbiota | |
| P478 | volume | 348 |
| Q30367172 | 3-D Microwell Array System for Culturing Virus Infected Tumor Cells. |
| Q90099882 | A Comparison of Biopsy and Mucosal Swab Specimens for Examining the Microbiota of Upper Gastrointestinal Carcinoma |
| Q92721043 | A Customized At-Home Stool Collection Protocol for Use in Microbiome Studies Conducted in Cancer Patient Populations |
| Q64105962 | A Preliminary Study of Microbiota Diversity in Saliva and Bronchoalveolar Lavage Fluid from Patients with Primary Bronchogenic Carcinoma |
| Q89408691 | A concurrent subtractive assembly approach for identification of disease associated sub-metagenomes |
| Q61458754 | A marginalized two-part Beta regression model for microbiome compositional data |
| Q96292431 | A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence |
| Q52579506 | A systems biology approach to predict and characterize human gut microbial metabolites in colorectal cancer. |
| Q38815212 | Adapting Cancer Immunotherapy Models for the Real World |
| Q103836778 | Advances in bladder cancer biology and therapy |
| Q64949336 | AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper. |
| Q33767631 | Alteration of the gut microbiota in Chinese population with chronic kidney disease |
| Q59335555 | Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function |
| Q58733994 | Alterations of fecal bacterial communities in patients with lung cancer |
| Q90148492 | Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples |
| Q57108408 | Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? |
| Q48413947 | Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events? |
| Q61806805 | Assessment of the oral health behavior, knowledge and status among dental and medical undergraduate students: a cross-sectional study |
| Q91899599 | Association Between Anti-bacterial Drug Use and Digestive System Neoplasms: A Systematic Review and Meta-analysis |
| Q55411186 | Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer. |
| Q91837173 | Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study |
| Q90183488 | Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study |
| Q38997272 | Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue |
| Q42551613 | Autophagy, microbiota and intestinal oncogenesis |
| Q57485135 | Bacteriophages Synergize with the Gut Microbial Community To Combat |
| Q57923684 | Beyond Metabolomics: A Review of Multi-Omics-Based Approaches |
| Q36210928 | Biological Mechanisms for the Effect of Obesity on Cancer Risk: Experimental Evidence |
| Q64250623 | CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy |
| Q36204706 | CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function |
| Q61800984 | Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors |
| Q97546137 | Cancer systems immunology |
| Q39146396 | Carcinogenesis and therapeutics: the microbiota perspective. |
| Q35943509 | Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses |
| Q57162847 | Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges |
| Q48182864 | Colorectal Cancers: An Update on Their Molecular Pathology |
| Q35884122 | Colorectal cancer: role of commensal bacteria and bystander effects |
| Q64075100 | Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma |
| Q38685345 | Comparison of Fecal Microbial Composition and Antibiotic Resistance Genes from Swine, Farm Workers and the Surrounding Villagers |
| Q90128284 | Complex interactions between the microbiome and cancer immune therapy |
| Q90177412 | Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX |
| Q52583327 | Computer-guided design of optimal microbial consortia for immune system modulation. |
| Q55012882 | Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. |
| Q47321577 | Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. |
| Q91884674 | Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure |
| Q38963228 | Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? |
| Q59350458 | Diagnostic Potential and Interactive Dynamics of the Colorectal Cancer Virome |
| Q38763940 | Diet, nutrition, and cancer: past, present and future |
| Q91808273 | Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer |
| Q92059945 | Dietary patterns and cancer risk |
| Q96952888 | Differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q57805748 | Diversity of macaque microbiota compared to the human counterparts |
| Q90459275 | Dynamic interactions within the host-associated microbiota cause tumor formation in the basal metazoan Hydra |
| Q42170770 | Editorial on "Cancer and the microbiota" published in Science |
| Q55439924 | Effect of the dietary polyacetylenes falcarinol and falcarindiol on the gut microbiota composition in a rat model of colorectal cancer. |
| Q39094764 | Elements of cancer immunity and the cancer-immune set point |
| Q52597550 | Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. |
| Q59411245 | Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention |
| Q35884126 | Epigenetic Segregation of Microbial Genomes from Complex Samples Using Restriction Endonucleases HpaII and McrB. |
| Q38985869 | Epigenetic Treatment of Persistent Viral Infections. |
| Q94539008 | Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma |
| Q58575956 | Evaluating gut microbiota profiles from archived fecal samples |
| Q92724691 | Evaluation of cancer risk in patients with periodontal diseases |
| Q38752482 | Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. |
| Q89856829 | From Beyond the Pale to the Pale Riders: The Emerging Association of Bacteria with Oral Cancer |
| Q64101674 | From trash to treasure: detecting unexpected contamination in unmapped NGS data |
| Q46329298 | Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy |
| Q40603067 | Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis |
| Q91706109 | Fusobacterium nucleatum prevents apoptosis in colorectal cancer cells via the ANO1 pathway |
| Q91651518 | Gene Expression Analysis of Human Papillomavirus-Associated Colorectal Carcinoma |
| Q36062322 | Genomic Diversity of Enterotoxigenic Strains of Bacteroides fragilis |
| Q38602944 | Group 3 innate lymphoid cells: regulating host-commensal bacteria interactions in inflammation and cancer |
| Q57191774 | Grow With the Challenge - Microbial Effects on Epithelial Proliferation, Carcinogenesis, and Cancer Therapy |
| Q51764655 | Gut Microbiota Alteration After Long-Term Consumption of Probiotics in the Elderly. |
| Q90043564 | Gut Microbiota and Cancer of the Host: Colliding Interests |
| Q38949434 | Gut Microbiota, Inflammation, and Colorectal Cancer. |
| Q52643740 | Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders. |
| Q47447695 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. |
| Q97541115 | Gut microbiome, big data and machine learning to promote precision medicine for cancer |
| Q48113441 | Gut microbiome: a new player in gastrointestinal disease |
| Q61798265 | Gut microbiota community characteristics and disease-related microorganism pattern in a population of healthy Chinese people |
| Q35935129 | Gut microbiota, obesity and diabetes. |
| Q91971762 | HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases |
| Q26799980 | HUMAN MICROBIOTA. Small molecules from the human microbiota |
| Q35913997 | High-throughput sequencing reveals the core gut microbiome of Bar-headed goose (Anser indicus) in different wintering areas in Tibet |
| Q36672253 | Hospital Readmissions in Patients With Carbapenem-Resistant Klebsiella pneumoniae |
| Q28069401 | Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine |
| Q52374120 | Human Gut Microbiota and Gastrointestinal Cancer. |
| Q50178446 | Human Intestinal Microbiota and Colorectal Cancer: Moving Beyond Associative Studies. |
| Q40372598 | Identification of Merkel Cell Polyomavirus from a Patient with Acute Myeloid Leukemia |
| Q35854627 | Identification of low abundance microbiome in clinical samples using whole genome sequencing |
| Q93270162 | Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma |
| Q64102315 | Impact of Preservation Method and 16S rRNA Hypervariable Region on Gut Microbiota Profiling |
| Q55031984 | Impact of a 3-Months Vegetarian Diet on the Gut Microbiota and Immune Repertoire. |
| Q96135720 | Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models |
| Q48285353 | Increased Risk for Colon Polyps in Patients with Reflux Disease. |
| Q38682775 | Increased cancer risk in patients with periodontitis. |
| Q53688957 | Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. |
| Q92560950 | Innate lymphoid cells: A potential link between microbiota and immune responses against cancer |
| Q33632567 | Insights into the role of the intestinal microbiota in colon cancer |
| Q40378202 | Interaction of Ethnicity and H. pylori Infection in the Occurrence of Microscopic Colitis |
| Q35916333 | Intestinal Microbiota in Inflammatory Bowel Disease and Carcinogenesis: Implication for Therapeutics |
| Q92264245 | Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma |
| Q46353757 | Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma |
| Q89658492 | Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells |
| Q35962328 | Know your neighbor: Microbiota and host epithelial cells interact locally to control intestinal function and physiology. |
| Q37304964 | Leveraging premalignant biology for immune-based cancer prevention |
| Q94672157 | Linking gut microbiota with the human diseases |
| Q50125735 | Linking the Gut Microbiota to Bone Health in Anorexia Nervosa. |
| Q42249371 | Liver Flukes and the Microbiota in Cancer |
| Q35918478 | Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults |
| Q47133700 | Matrix metalloproteinase MMP9 maintains epithelial barrier function and preserves mucosal lining in colitis associated cancer |
| Q93333202 | Maximizing the Utility of Cancer Transcriptomic Data |
| Q39056719 | Measuring the diversity of the human microbiota with targeted next-generation sequencing |
| Q92541923 | MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities |
| Q40101851 | Microbial infection, inflammation and epithelial ovarian cancer |
| Q36138105 | Microbiome, a new dimension in cancer research |
| Q54242488 | Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study. |
| Q38935534 | Microbiota as a mediator of cancer progression and therapy. |
| Q90443956 | Microbiota in cancer development and treatment |
| Q50263790 | Microbiota in digestive cancers: our new partner? |
| Q55554558 | Microbiota, Epithelium, Inflammation, and TGF-β Signaling: An Intricate Interaction in Oncogenesis. |
| Q54704401 | Microbiota, parasites and immunity. |
| Q59795977 | Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression |
| Q58591398 | Model colibactins exhibit human cell genotoxicity in the absence of host bacteria |
| Q46353300 | Mucosa-associated microbiota signature in colorectal cancer |
| Q58726363 | Mucosal microbiota of intestinal polyps reveals putative biomarkers of colorectal cancer |
| Q46265634 | Mucus models to evaluate the diffusion of drugs and particles. |
| Q92759091 | Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis |
| Q33888179 | N-(3-oxododecanoyl)-L-homoserine lactone interactions in the breast tumor microenvironment: Implications for breast cancer viability and proliferation in vitro. |
| Q40498026 | Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. |
| Q95923729 | Novel Forms of Immunomodulation for Cancer Therapy |
| Q39024774 | Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation |
| Q36734737 | Obesity and Cancer: Concepts and Challenges |
| Q51733135 | Of Microbes and Minds: A Narrative Review on the Second Brain Aging. |
| Q35765830 | On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death |
| Q55302559 | Organoids Provide an Important Window on Inflammation in Cancer. |
| Q92639044 | Parasite-microbe-host interactions and cancer risk |
| Q36830811 | Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study |
| Q40468912 | Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. |
| Q90487338 | Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway |
| Q40881730 | Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells. |
| Q89529814 | Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa |
| Q38857539 | Precancer Atlas to Drive Precision Prevention Trials. |
| Q100464717 | Preliminary insights into the impact of primary radiochemotherapy on the salivary microbiome in head and neck squamous cell carcinoma |
| Q64251926 | Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework |
| Q92865756 | Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy |
| Q88764776 | Publisher Correction: The gut-liver axis and the intersection with the microbiome |
| Q59793303 | Qualitative and Quantitative DNA- and RNA-Based Analysis of the Bacterial Stomach Microbiota in Humans, Mice, and Gerbils |
| Q47153549 | Quinones are growth factors for the human gut microbiota |
| Q91807970 | Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers |
| Q40085659 | Regulation of life span by the gut microbiota in the short-lived African turquoise killifish |
| Q38847228 | Regulation of the T Cell Response by CD39. |
| Q46130970 | Reply to AT Wijayabahu |
| Q55243343 | Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. |
| Q64078088 | Risk of cancer in patients with constipation |
| Q91907099 | Role of Microbiome in Modulating Immune Responses in Cancer |
| Q90225030 | Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms |
| Q36243299 | Role of intestinal microbiota and metabolites on gut homeostasis and human diseases |
| Q64077761 | Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship |
| Q26747710 | Role of the microbiome in non-gastrointestinal cancers |
| Q47838749 | SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model |
| Q47406754 | Safety assessment of transgenic canola RF3 with bar and barstar gene on Sprague-Dawley (SD) rats by 90-day feeding test |
| Q90331718 | Seven facts and five initiatives for gut microbiome research |
| Q38808593 | Sexual dimorphism in cancer |
| Q90694690 | Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions |
| Q42772508 | Specificity and diversity of the mouse Peyer's patch mononuclear phagocyte system. |
| Q40124105 | Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. |
| Q36748438 | Structural Characterization and Bioactivity Analysis of the Two-Component Lantibiotic Flv System from a Ruminant Bacterium |
| Q38605864 | Structure and Functional Analysis of ClbQ, an Unusual Intermediate-Releasing Thioesterase from the Colibactin Biosynthetic Pathway |
| Q58769349 | Study of Microbiomes in Aseptically Collected Samples of Human Breast Tissue Using Needle Biopsy and the Potential Role of Tissue Microbiomes for Promoting Malignancy |
| Q64251029 | Subclinical Lipopolysaccharide from Enteritidis Induces Dysregulation of Bioactive Substances from Selected Brain Sections and Glands of Neuroendocrine Axes |
| Q64114197 | Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A |
| Q37307560 | Synchronized cycles of bacterial lysis for in vivo delivery |
| Q37713498 | Systematic evaluation of immune regulation and modulation |
| Q40291361 | TLR4 Promotes Breast Cancer Metastasis via Akt/GSK3β/β-Catenin Pathway upon LPS Stimulation |
| Q38792334 | Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions |
| Q36937525 | Taxonomer: an interactive metagenomics analysis portal for universal pathogen detection and host mRNA expression profiling |
| Q37685690 | Technologies for Proteome-Wide Discovery of Extracellular Host-Pathogen Interactions |
| Q26766414 | The Challenge and Potential of Metagenomics in the Clinic |
| Q36468964 | The Emerging Hallmarks of Cancer Metabolism |
| Q38791732 | The Ethnic Distribution of Sessile Serrated Polyps in the United States Is Inversely Associated with H. pylori Prevalence |
| Q92353620 | The Gut Microbiota Affects Host Pathophysiology as an Endocrine Organ: A Focus on Cardiovascular Disease |
| Q92800116 | The Inducible Response of the Nematode Caenorhabditis elegans to Members of Its Natural Microbiota Across Development and Adult Life |
| Q89587168 | The Microbiome as a Component of the Tumor Microenvironment |
| Q98735532 | The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion |
| Q52597305 | The New Frontier: the Intestinal Microbiome and Surgery. |
| Q51736365 | The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. |
| Q92441329 | The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer |
| Q64273608 | The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another's Growth |
| Q90923159 | The Urinary Microbiome: Implications in Bladder Cancer Pathogenesis and Therapeutics |
| Q35955043 | The diet-microbiota-metabolite axis regulates the host physiology |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q37634459 | The female urinary microbiota, urinary health and common urinary disorders. |
| Q47425267 | The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review |
| Q88634168 | The gut-liver axis and the intersection with the microbiome |
| Q26749316 | The healthy human microbiome |
| Q58762649 | The implementation of omics technologies in cancer microbiome research |
| Q40333157 | The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation |
| Q30248605 | The intestinal microbiome and surgical disease. |
| Q89767716 | The microbiome and gynaecological cancer development, prevention and therapy |
| Q35954984 | The microbiome and its potential as a cancer preventive intervention |
| Q92180014 | The microbiome, cancer, and cancer therapy |
| Q64266826 | The microbiota and microbiome in pancreatic cancer: more influential than expected |
| Q46266500 | The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. |
| Q99241167 | The role of non-H. pylori bacteria in the development of gastric cancer |
| Q90376906 | The role of the brain-gut-microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders |
| Q39290620 | The role of the microbiome in cancer development and therapy |
| Q33918472 | The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study |
| Q64247319 | The significance of microbiome in personalized medicine |
| Q58783075 | The urinary microbiome associated with bladder cancer |
| Q91212051 | The virtuous cycle of human genetics and mouse models in drug discovery |
| Q38756772 | Therapy-induced microenvironmental changes in cancer |
| Q41986568 | Transmission of a common intestinal neoplasm in zebrafish by cohabitation. |
| Q47140201 | Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor/progenitor cells. |
| Q55396890 | Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. |
| Q49724432 | Variations among Streptococcus gallolyticus subsp. gallolyticus strains in connection with colorectal cancer. |
| Q102220195 | Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells |
| Q58095301 | er promotes colorectal tumorigenesis through the action of cytolethal distending toxin |
| Q89576500 | γδ T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer |
Search more.